Zealand Pharma A/S

225 articles with Zealand Pharma A/S

• Zealand Pharma Today Hosts a Capital Market Day and Site Visit

  4/6/2011

• Zealand Pharma and Pepscan Awarded EU Grant of EUR 0.9 Million for the Joint Development of Novel Peptide Drugs

  3/22/2011

• Zealand Pharma Release: Financial Statements for the Year Ending 31 December 2010

  2/10/2011

• Sanofi-Aventis (France), Zealand Pharma Diabetes Drug Worked as Well as Eli Lilly and Company's Byetta in Study

  2/2/2011

• Zealand Pharma Receives Milestone Payment from Helsinn Healthcare SA

  12/9/2010

• Zealand Pharma Mulls IPO, Seen Worth up to $560 Million

  10/21/2010

• Positive Phase I Data for Zealand Pharma 's ZP1848 in Crohn's Disease

  10/15/2010

• Sanofi-Aventis (France) Announce Partner Zealand Pharma Has Positive Study Findings from Lixisenatide in First Phase III Get Goal Trial for Type 2 Diabetes

  9/20/2010

• Zealand Pharma Announces An Extension Of The Lixisenatide Global Licensing Agreement With Sanofi-Aventis K.K. For Type-2 Diabetes

  6/8/2010

• Zealand Pharma : Annual Review for 2009

  5/6/2010

• Positive Phase III Diabetes Data with Lixisenatide Announced by Zealand Pharma 's Partner Sanofi-Aventis (France)

  4/15/2010

• Zealand Pharma Announces Augmentation of its Management Team as it Continues its Growth Strategy

  3/8/2010

• Sanofi-Aventis (France) May Take Stake in Zealand Pharma for up to $143 Million

  12/23/2009

• Zealand Pharma Advances A New Generation Of Type 2 Diabetes Treatment

  9/1/2009

• Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs

  4/14/2009

• Vyteris, Inc. and Zealand Pharma Announce Agreement on Active Transdermal Patch for Peptide Drugs

  4/14/2009

• Zealand Pharma Receives Frost & Sullivan 2008 European Research & Development Award

  3/18/2009

• Helsinn Healthcare SA Announces Partnering Agreement for ZP1846, a Novel GLP-2 Agonist from Zealand Pharma

  12/11/2008

• Zealand Pharma and Helsinn Healthcare SA Sign a €140 Million (US$176.8 Million) Partnering Agreement for ZP1846, a Novel GLP-2 Agonist

  12/2/2008

• Zealand Pharma Appoints New Chief Executive Officer

  8/28/2008